78 related articles for article (PubMed ID: 25156059)
1. Prognostic significance of YWHAZ expression in localized prostate cancer.
Rüenauver K; Menon R; Svensson MA; Carlsson J; Vogel W; Andrén O; Nowak M; Perner S
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):310-4. PubMed ID: 25156059
[TBL] [Abstract][Full Text] [Related]
2. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of OCT4 expression in patients with prostate cancer.
Kosaka T; Mikami S; Yoshimine S; Miyazaki Y; Daimon T; Kikuchi E; Miyajima A; Oya M
Hum Pathol; 2016 May; 51():1-8. PubMed ID: 27067776
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer.
Bao BY; Lin VC; Huang SH; Pao JB; Chang TY; Lu TL; Lan YH; Chen LM; Ting WC; Yang WH; Hsieh CJ; Huang SP
Ann Surg Oncol; 2010 Jun; 17(6):1675-81. PubMed ID: 20204532
[TBL] [Abstract][Full Text] [Related]
7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
8. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
Menon R; Deng M; Rüenauver K; Queisser A; Peifer M; Pfeifer M; Offermann A; Boehm D; Vogel W; Scheble V; Fend F; Kristiansen G; Wernert N; Oberbeckmann N; Biskup S; Rubin MA; Adler D; Perner S
J Pathol; 2013 Dec; 231(4):505-16. PubMed ID: 24114522
[TBL] [Abstract][Full Text] [Related]
9. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
Wang Q; Diao X; Sun J; Chen Z
Urol Oncol; 2013 Apr; 31(3):312-7. PubMed ID: 21367627
[TBL] [Abstract][Full Text] [Related]
10. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
11. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer.
Yip PY; Kench JG; Rasiah KK; Benito RP; Lee CS; Stricker PD; Henshall SM; Sutherland RL; Horvath LG
Prostate; 2011 Nov; 71(15):1638-45. PubMed ID: 21432866
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
14. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
[TBL] [Abstract][Full Text] [Related]
15. Differential tumor expression of inhibitor of differentiation-1 in prostate cancer patients with extreme clinical phenotypes and prognostic implications.
Ponz-Sarvisé M; Castañón E; Panizo-Santos A; Redrado M; López I; Rosell D; Gil-Aldea I; Calvo A; Nguewa PA; Gil-Bazo I
Clin Genitourin Cancer; 2014 Apr; 12(2):87-93. PubMed ID: 24129125
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy.
Ren GF; Tang L; Yang AQ; Jiang WW; Huang YM
Histol Histopathol; 2014 Apr; 29(4):535-42. PubMed ID: 24222185
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer.
Ricciardelli C; Quinn DI; Raymond WA; McCaul K; Sutherland PD; Stricker PD; Grygiel JJ; Sutherland RL; Marshall VR; Tilley WD; Horsfall DJ
Cancer Res; 1999 May; 59(10):2324-8. PubMed ID: 10344737
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH
J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]